Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab

SW Ting, YC Chen, YH Huang - Clinical Drug Investigation, 2018 - Springer
Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …
被引用次数：50 相关文章

Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab

SW Ting, YC Chen, YH Huang - Clinical drug …, 2018 - pubmed.ncbi.nlm.nih.gov
Background and objectives Ustekinumab is used to treat moderate-to-severe psoriasis by
blocking the interleukin-12/23 pathway, which is also essential against intracellular …

Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab

SW Ting, YC Chen, YH Huang - Clinical Drug Investigation, 2018 - search.proquest.com
Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …

Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.

SW Ting, YC Chen, YH Huang - Clinical Drug Investigation, 2018 - europepmc.org
Results Ninety-three psoriasis patients receiving ustekinumab were included. The average
duration of treatment and follow-up was 24±12 months. There were 39 patients classified as …

Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab.

SW Ting, YC Chen, YH Huang - Clinical Drug Investigation, 2018 - cabdirect.org
Background and Objectives: Ustekinumab is used to treat moderate-to-severe psoriasis by
blocking the interleukin-12/23 pathway, which is also essential against intracellular …